Literature DB >> 3308476

Do proteases play a role in cancer invasion and metastasis?

M J Duffy1.   

Abstract

The main difference between a benign and malignant tumor is the ability of the malignant form to invade normal tissue and spread or metastasize to distant sites throughout the body. It is the ability to form metastasis which makes cancer such a difficult disease to treat. Evidence suggesting that proteolytic enzymes are involved in cancer spread is as follows: proteases are involved in normal destructive events and tissue remodelling, correlations exist between different protease activities and metastatic potential in model tumor systems, inhibitors and antibodies against proteases inhibit metastasis in model systems and the finding of highest levels of protease activity at the invading front in tumors. The most likely mechanism by which proteases could mediate metastasis is by catalyzing degradation of the extracellular matrix and basement membranes. It is concluded that if proteases could be proved to play a role in the spread of human cancers, inhibition of these enzymes could open up new therapeutic approaches for the control of malignancy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3308476     DOI: 10.1016/0277-5379(87)90326-9

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  13 in total

1.  Isolation, characterization, and properties of a trypsin-chymotrypsin inhibitor from amaranth seeds.

Authors:  S Tamir; J Bell; T H Finlay; E Sakal; P Smirnoff; S Gaur; Y Birk
Journal:  J Protein Chem       Date:  1996-02

Review 2.  The role of proteolytic enzymes in cancer invasion and metastasis.

Authors:  M J Duffy
Journal:  Clin Exp Metastasis       Date:  1992-05       Impact factor: 5.150

Review 3.  Interactions between cancer cells and the microvasculature: a rate-regulator for metastasis.

Authors:  L Weiss; F W Orr; K V Honn
Journal:  Clin Exp Metastasis       Date:  1989 Mar-Apr       Impact factor: 5.150

4.  Discovery of Pyridyl Bis(oxy)dibenzimidamide Derivatives as Selective Matriptase Inhibitors.

Authors:  Rajeev Goswami; Subhendu Mukherjee; Gerd Wohlfahrt; Chakshusmathi Ghadiyaram; Jwala Nagaraj; Beeram Ravi Chandra; Ramesh K Sistla; Leena K Satyam; Dodheri S Samiulla; Anu Moilanen; Hosahalli S Subramanya; Murali Ramachandra
Journal:  ACS Med Chem Lett       Date:  2013-10-07       Impact factor: 4.345

5.  Low E-cadherin and beta-catenin expression correlates with increased spontaneous and artificial lung metastases of murine carcinomas.

Authors:  T Akimoto; S Kawabe; A Grothey; L Milas
Journal:  Clin Exp Metastasis       Date:  1999-03       Impact factor: 5.150

Review 6.  Fibrinolytic mechanisms in tumor growth and spreading.

Authors:  T Südhoff; W Schneider
Journal:  Clin Investig       Date:  1992-08

7.  Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods.

Authors:  C Bouchet; F Spyratos; K Hacène; L Durcos; V Bécette; J Oglobine
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

8.  Production of immunoreactive polymorphonuclear leucocyte elastase in human breast cancer cells: possible role of polymorphonuclear leucocyte elastase in the progression of human breast cancer.

Authors:  J I Yamashita; M Ogawa; S Ikei; H Omachi; S I Yamashita; T Saishoji; K Nomura; H Sato
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

9.  Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.

Authors:  C Bouchet; F Spyratos; P M Martin; K Hacène; A Gentile; J Oglobine
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

10.  Breast cancer prognosis is poor when total plasminogen activator activity is low.

Authors:  J Yamashita; M Ogawa; K Inada; S Yamashita; Y Nakashima; T Saishoji; K Nomura
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.